Clinical Trial Detail

NCT ID NCT03866239
Title A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

colon adenocarcinoma

rectum adenocarcinoma

Therapies

Atezolizumab + Obinutuzumab + RO6958688

Age Groups: adult senior

No variant requirements are available.